- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Foster City Today
By the People, for the People
Banque Pictet & Cie SA Boosts Gilead Sciences Stake by 168.8%
The Swiss bank significantly increased its position in the biopharmaceutical company during Q4 2025.
Apr. 2, 2026 at 7:34am
Got story updates? Submit your updates here. ›
Banque Pictet & Cie SA, a Swiss private bank, raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 168.8% in the fourth quarter of 2025, according to a recent SEC filing. The bank now owns 227,007 shares of the biopharmaceutical company's stock, valued at $27.86 million.
Why it matters
Gilead Sciences is a major player in the pharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. Banque Pictet & Cie SA's substantial increase in its Gilead position suggests the bank sees strong growth potential in the company's portfolio and pipeline.
The details
The filing shows that Banque Pictet & Cie SA acquired an additional 142,543 shares of Gilead Sciences during the fourth quarter, bringing its total holdings to 227,007 shares. This represents a significant 168.8% increase in the bank's position in the biopharmaceutical company.
- Banque Pictet & Cie SA increased its Gilead Sciences stake in the fourth quarter of 2025.
- The bank's holdings were valued at $27.86 million at the end of the reporting period.
The players
Banque Pictet & Cie SA
A Swiss private bank that manages assets for high-net-worth individuals and institutional clients.
Gilead Sciences, Inc.
A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, particularly antiviral therapies for HIV and viral hepatitis.
The takeaway
Banque Pictet & Cie SA's significant increase in its Gilead Sciences stake suggests the bank sees strong growth potential in the company's pharmaceutical portfolio and pipeline, underscoring Gilead's position as a major player in the biopharmaceutical industry.
